Cytomegalovirus colitis in a patient treated with efalizumab

Dermatology

Volumn 218, Issue 1, 2008, Pages 84-85

  Caudron, Anne ^a   Lok, Catherine ^a   Clabaut, Angèle ^a   Desblache, Julien ^a   Heyman, Bertrand ^b   Viseux, Valérie ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b Gastroenterology Service   (France)

Author keywords

Cytomegalovirus colitis; Efalizumab; Psoriasis

Indexed keywords

C REACTIVE PROTEIN; EFALIZUMAB; ETANERCEPT; ETRETIN; GANCICLOVIR; IMMUNOGLOBULIN M; METHOTREXATE; METHOXSALEN; VALGANCICLOVIR;

ABDOMINAL PAIN; AGED; CASE REPORT; COLITIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LETTER; LYMPHOCYTOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; PUVA; RELAPSE;

AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; COLITIS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS;

EID: 58149103170     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000174038     Document Type: Letter

References (15)

1. Technical file of Raptiva (efalizumab). San Francisco, Gentech, 2005.
2. Rivas-Rodriguez R, Romero-Alonso MM, Gabella-Bazarot E, Sanchez-Gomez E: Efalizumab-induced aseptic meningitis. Farm Hosp 2007;31:70-71.
3. Descamps V: Efalizumab: Raptiva®. Ann Dermatol Venereol 2007;134:982-987.
4. Scheinfeld N: Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006;5:197-209.
5. Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, Kwon P, et al: A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology 2006;213:204-214.
6. Langley RG, Carey WP, Rafal ES, Tyring SK, Caro I, Wang X, Wetherill G, Gordon KB: Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther 2005;27:1317-1328.
7. Balato A, Balato N, Patruno C, Gallo L, Ayala F: Visceral leishmaniasis infection in a patient with psoriasis treated with efalizumab. Dermatology 2008;217:360-361.
8. Weisenseel P, Kuznetsov AV, Flaig M, Prinz JC: Disseminated eruptive giant mollusca contagiosa in an adult psoriasis patient during efalizumab therapy. Dermatology 2008;217:85-86.
9. Gottlieb AB, Miller B, Lowe N, et al: Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis. J Cutan Med Surg 2003;7:198-207.
10. Grundy JE, Pahal GS, Akbar AN: Increased adherence of CD2 peripheral blood lymphocytes to cytomegalovirus-infected fibroblasts is blocked by anti-LFA-3 antibody. Immunology 1993;78:413-420.
11. Santos-Juanes J, Coto-Segura P, Mallo S, Galache C, Soto J: Multiple eruptive dermatofibromas in a patient receiving efalizumab. Dermatology 2008;216:363.
12. Sari I, Birlik M, Gonen C, Akar S, Gurel D, Onen F, Akkoc N: Cytomegalovirus colitis in a patient with Behçet's disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol 2008;14:2912-2914.
13. Tnani N, Massoumi A, Lortholary O, Soussan P, Prinseau J, Baglin A, Hanslik T: Management of cytomegalovirus infections in patients treated with immunosuppressive drugs for chronic inflammatory diseases. Rev Med Int 2008;29:305-310.
14. Helbling D, Breitbach TH, Krause M: Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2002;14:1393-1395.
15. Carter D, Olchovsky D, Pokroy R, Ezra D: Cytomegalovirus-associated colitis causing diarrhea in an immunocompetent patient. World J Gastroenterol 2006;12:6898-6899.